Press Release
2024
2023
2022
2021
2020
NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China
GUANGZHOU, China, October 11, 2024—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), an innovative company in the field of precision oncology, and Dizal, a global biopharmaceutical company focused on malignant tumors and immunological...
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays...
Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics
On October 25, 2023, during the 2023 Boehringer Ingelheim China R&D Day event, Burning Rock and Boehringer Ingelheim officially signed the Master Service Agreement (MSA) in the field of oncology companion diagnostics. This agreement aims to provide Chinese...
Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test
GUANGZHOU, China, Oct. 15, 2023 -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that followed an earlier Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for its...
Burning Rock announced a China collaboration with AstraZeneca
On August 9, 2023, Burning Rock (NASDAQ/LSE: BNR) announced a China collaboration with AstraZeneca (NASDAQ/LSE/STO: AZN). As part of the collaboration, Burning Rock will leverage its leading detection technologies and high-quality, standardized testing capabilities to...
Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test
IRVINE, Calif. Jan.03, 2023 - Burning Rock (NASDAQ/LSE: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its OverC™ Multi-Cancer Detection Blood Test (MCDBT) has been...
Burning Rock Announces the Launch of China’s First Prospective Interventional Validation Study on Multi-Cancer Early Detection - the PREVENT Study
CHENGDU, China, June 30, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced the...
Burning Rock Receives CE Mark Approval for Three NGS Tumor Kits
IRVINE, Calif. June 1, 2022--Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) announced that the Company had received CE mark approval for three self-developed next generation sequencing (NGS) kits, namely, “OncoScreen™ Plus Cancer Mutation...
Burning Rock Receives CE Mark for its OverC™ Multi-Cancer Detection Blood Test Kit
IRVINE, Calif. June 1, 2022--Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) announced that it has received CE marking for its OverC™ Multi-Cancer Detection Blood Test manufactured in both the US and China facilities (Identification Number:...